| A028 |
Alemtuzumab
Featured
|
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. |
|
| A124 |
Trastuzumab emtansine
Featured
|
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer. |
|
| A273 |
Datopotamab deruxtecan
Featured
|
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity. |
|
| A125 |
Trastuzumab deruxtecan
Featured
|
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. |
|
| A724 |
Girentuximab
Featured
|
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). |
|
| A126 |
Evolocumab Biosimilar （Anti-PCSK9 Reference Antibody）
Featured
|
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases. |
|
| A127 |
Rovalpituzumab Biosimilar （Anti-DLL3 Reference Antibody）
Featured
|
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC). |
.png)
|
| A274 |
Patritumab deruxtecan
Featured
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1]. |
|
| A152 |
Codrituzumab-MMAE Biosimilar(Anti-GPC3 / Glypican-3 Reference Antibody)
Featured
|
Codrituzumab-MMAE, is an antibody-drug conjugate composed of a anti-GPC3 monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker. |
|
| A902 |
Necitumumab (anti-EGFR)
Featured
|
Necitumumab (anti-EGFR) is an epidermal growth factor receptor (EGFR) antagonist that can be used in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer. |
|
| A050 |
Licaminlimab Biosimilar(Anti-TNFSF2 / TNFa Reference Antibody )
Featured
|
Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation. |
|
| A051 |
Gremubamab Biosimilar (Anti-PcrV Reference Antibody )
Featured
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections. |
|
| A052 |
Nirsevimab Biosimilar (Anti-RSV Reference Antibody)
Featured
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections. |
.png)
|
| A053 |
Aselizumab Biosimilar (Anti-L-selectin Reference Antibody)
Featured
|
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma. |
.png)
|
| A054 |
Raxibacumab Biosimilar（Anti-PA Reference Antibody）
Featured
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research. |
.png)
|
| A055 |
Afelimomab Biosimilar （Anti-TNFSF2 / TNFa Reference Antibody）
Featured
|
Afelimomab (MAK 195F) is an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment. Afelimomab can be used for the research of sepsis. |
.png)
|
| A056 |
Agensys patent anti-158P1D7 Biosimilar （Anti-158P1D7 Reference Antibody）
Featured
|
|
|
| A057 |
Numab patent anti-HSA Biosimilar（Anti-Albumin Reference Antibody）
Featured
|
|
|
| A058 |
Birtamimab Biosimilar （Anti-Amyloid Alpha Reference Antibody）
Featured
|
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis. |
|
| A060 |
Cantuzumab Biosimilar （Anti-CanAg Reference Antibody）
Featured
|
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493). |
|
| A061 |
VLST-002 Biosimilar （Anti-CCL5 / RANTES Reference Antibody）
Featured
|
|
|
| A062 |
R707 Biosimilar (Anti-CCR7 / CD197 Reference Antibody)
Featured
|
|
|
| A063 |
Ofatumumab Biosimilar (Anti-CD20 Reference Antibody)
Featured
|
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes. |
.png)
|
| A064 |
Genefrontier patent anti-CD69 Biosimilar (Anti-CD69 Reference Antibody)
Featured
|
|
|
| A065 |
KHK-2898 Biosimilar (Anti-CD98 Reference Antibody)
Featured
|
|
|
| A066 |
CergutuzumAb Biosimilar (Anti-CEACAM5 / CEA / CD66e Reference Antibody)
Featured
|
|
|
| A067 |
Immunomedics patent anti-CEACAM5 (Class III) Biosimilar (Anti-CEACAM5 / CEA / CD66e Reference Antibody)
Featured
|
|
|
| A068 |
IMAB027 Biosimilar (Anti-CLDN6 Reference Antibody)
Featured
|
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6+ ovarian and testicular cancer cell lines. |
|
| A069 |
AB1-11 Biosimilar (Anti-CLDN6 Reference Antibody)
Featured
|
|
|
| A070 |
IM-301 Biosimilar (Anti-CLDN6 Reference Antibody)
Featured
|
|
|
